Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE)

One of hepatocellular carcinoma (HCC) therapeutic modality is transarterial chemoembolization (TACE). The albumin-bilirubin (ALBI) grade is amongst the newest of prognostic scores published to predict survival. The aim of this study was to analzye the ALBI grade as a three-month survival predictor in HCC patients after initial TACE. This was a retrospective analytic observational study identifying patients that underwent initial TACE from January 2013 to December 2017 in Dr. Soetomo General Hospital, Surabaya. Data were collected before treatment and analyzed to evaluate ALBI grade as a survival predictor. Out of 134 HCC patients, the subjects consisted of 100 (74.6%) male subjects and 34 (25.4%) female subjects. There were 25 (18.7%), 98 (73.1%), dan 11 (8.2%) subjects who were classified into to ALBI 1, ALBI 2, and ALBI 3, respectively, with a median ALBI score of -2.295. The ALBI grade was significantly associated with the three-month survival variable (p = 0.01; CI 95%). Using the ROC curve, we have determined a new cut-off point. The group of ALBI score ≤ -2.27 had an odds ratio of 2.549 (CI 95% 1.232-5.273) for three-month survival. The ALBI grade was associated with three-month survival after initial TACE in patients with HCC.